Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

PG. Richardson, A. Perrot, JS. Miguel, M. Beksac, I. Spicka, X. Leleu, F. Schjesvold, P. Moreau, MA. Dimopoulos, SY. Huang, J. Minarik, M. Cavo, HM. Prince, S. Macé, R. Zhang, F. Dubin, MC. Morisse, KC. Anderson

. 2024 ; 109 (7) : 2239-2249. [pub] 20240701

Language English Country Italy

Document type Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24019947

The primary and prespecified updated analyses of ICARIA-MM (clinicaltrial gov. Identifier: NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase III study included patients who had received and failed ≥2 previous therapies, including lenalidomide and a proteasome inhibitor. Between January 10, 2017, and February 2, 2018, 307 patients were randomized (1:1) to isatuximab-pomalidomide-dexamethasone (Isa-Pd; N=154) or Pd (N=153), stratified based on age (<75 vs. ≥75 years) and number of previous lines of therapy (2-3 vs. >3). At data cutoff for the final OS analysis after 220 OS events (January 27, 2022), median follow-up duration was 52.4 months. Median OS was 24.6 months (95% confidence interval [CI]: 20.3-31.3) with Isa-Pd and 17.7 months (95% CI: 14.4- 26.2) with Pd (hazard ratio=0.78; 95% CI: 0.59-1.02; 1-sided P=0.0319). Despite subsequent daratumumab use in the Pd group and its potential benefit on PFS in the first subsequent therapy line, median PFS2 was significantly longer with Isa-Pd versus Pd (17.5 vs. 12.9 months; log-rank 1-sided P=0.0091). In this analysis, Isa-Pd continued to be efficacious and well tolerated after follow-up of approximately 52 months, contributing to a clinically meaningful, 6.9-month improvement in median OS in patients with relapsed/refractory multiple myeloma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019947
003      
CZ-PrNML
005      
20241024110832.0
007      
ta
008      
241015s2024 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2023.284325 $2 doi
035    __
$a (PubMed)38299578
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Richardson, Paul G $u Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. paul_richardson@dfci.harvard.edu
245    10
$a Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis / $c PG. Richardson, A. Perrot, JS. Miguel, M. Beksac, I. Spicka, X. Leleu, F. Schjesvold, P. Moreau, MA. Dimopoulos, SY. Huang, J. Minarik, M. Cavo, HM. Prince, S. Macé, R. Zhang, F. Dubin, MC. Morisse, KC. Anderson
520    9_
$a The primary and prespecified updated analyses of ICARIA-MM (clinicaltrial gov. Identifier: NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase III study included patients who had received and failed ≥2 previous therapies, including lenalidomide and a proteasome inhibitor. Between January 10, 2017, and February 2, 2018, 307 patients were randomized (1:1) to isatuximab-pomalidomide-dexamethasone (Isa-Pd; N=154) or Pd (N=153), stratified based on age (<75 vs. ≥75 years) and number of previous lines of therapy (2-3 vs. >3). At data cutoff for the final OS analysis after 220 OS events (January 27, 2022), median follow-up duration was 52.4 months. Median OS was 24.6 months (95% confidence interval [CI]: 20.3-31.3) with Isa-Pd and 17.7 months (95% CI: 14.4- 26.2) with Pd (hazard ratio=0.78; 95% CI: 0.59-1.02; 1-sided P=0.0319). Despite subsequent daratumumab use in the Pd group and its potential benefit on PFS in the first subsequent therapy line, median PFS2 was significantly longer with Isa-Pd versus Pd (17.5 vs. 12.9 months; log-rank 1-sided P=0.0091). In this analysis, Isa-Pd continued to be efficacious and well tolerated after follow-up of approximately 52 months, contributing to a clinically meaningful, 6.9-month improvement in median OS in patients with relapsed/refractory multiple myeloma.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $7 D009101
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    12
$a dexamethason $x aplikace a dávkování $7 D003907
650    12
$a thalidomid $x analogy a deriváty $x aplikace a dávkování $7 D013792
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a humanizované monoklonální protilátky $x aplikace a dávkování $x terapeutické užití $7 D061067
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dospělí $7 D000328
650    _2
$a chemorezistence $7 D019008
650    _2
$a výsledek terapie $7 D016896
650    _2
$a recidiva $7 D012008
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Perrot, Aurore $u CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse
700    1_
$a Miguel, Jesus San $u Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona
700    1_
$a Beksac, Meral $u Department of Hematology, Ankara University, Ankara, Turkey
700    1_
$a Spicka, Ivan $u General Faculty Hospital, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Leleu, Xavier $u Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex
700    1_
$a Schjesvold, Fredrik $u Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
700    1_
$a Moreau, Philippe $u Hematology Department, CHU Nantes, Nantes
700    1_
$a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
700    1_
$a Huang, Shang-Yi $u Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, and the Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy
700    1_
$a Prince, H Miles $u Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia
700    1_
$a Macé, Sandrine $u Sanofi, Vitry-sur-Seine
700    1_
$a Zhang, Rick $u Sanofi, Cambridge, MA
700    1_
$a Dubin, Franck $u Sanofi, Vitry-sur-Seine
700    1_
$a Morisse, Mony Chenda $u Sanofi, Cambridge, MA
700    1_
$a Anderson, Kenneth C $u Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 109, č. 7 (2024), s. 2239-2249
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38299578 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110826 $b ABA008
999    __
$a ok $b bmc $g 2202275 $s 1231920
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 109 $c 7 $d 2239-2249 $e 20240701 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options